Диссертация (1139774), страница 26
Текст из файла (страница 26)
Trihexyphenidyl(Artane): a Brazilian study of its abuse // Substance Use & Misuse. - 2005. - V. 40(4). P.473-82.191. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk //The Journal of Clinical Psychiatry. - 2007. - V. 68(4). - P. 8-13.192. Novalbos J., López-Rodríguez R., Román M., Gallego-Sandín S., Ochoa D.,Abad-SantosF.EffectsofCYP2D6genotypeonthepharmacokinetics,pharmacodynamics, and safety of risperidone in healthy volunteers // Journal ofPsychopharmacology.
- 2010. - V. 30(5). - Р. 504-11.193. Ogino S., Miyamoto S., Miyake N., Yamaguchi N. Benefits and limits ofanticholinergic use in schizophrenia: Focusing on its effect on cognitive function //Psychiatry and Clinical Neurosciences. - 2014. - V. 68. - P. 37-49.194. Oh J.D., Chase T.N. Glutamate-mediated striatal dysregulation and thepathogenesis of motor response complications in Parkinson’s disease // Amino Acids. 2002. - V.
23(1-3), P. 133-9.154195. Okumura Y., Noda T., Ito H. Antipsychotics prescribing patterns of withschizophrenia in Japan: using the national database of health insurance claiminformation and specified medical checkups [in Japanese] // Japanese Journal ofClinical Psychopharmacology. - 2013.
- V. 16. - P. 1201-15.196. Ösby U., Westman J., Hällgren J., Gissler M. Mortality trends in cardiovascularcauses in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010 //European Journal of Public Health. - 2016. - V. 26(5). - P. 867-71.197. Otani K., Horiuchi M., Kondo T., Kaneko S., Fukushima Y. Is the predispositionto neuroleptic malignant syndrome genetically transmitted? // British Journal ofPsychiatry. - 1991. - V.
158. - P. 850-3.198. Ozen M.E., Yumru M., Savas H.A., Cansel N., Herken H. Neuroleptic malignantsyndrome induced by ziprasidone on the second day of treatment // World Journal ofBiological Psychiatry. - 2007. - V. 8(1). - P. 42-4.199. Panagiotidis G., Arthur W., Lindh J.D., Dahl M.L., Sjöqvist F. Depot haloperidoltreatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6polymorphism on pharmacokinetics and treatment outcome // Therapeutic DrugMonitoring. - 2007. - V.
29(4). P. 417-22.200. Paparrigopoulos T., Tzavellas E., Ferentinos P., Mourikis I., Liappas J. Catatoniaas a risk factor for the development of neuroleptic malignant syndrome: report of a casefollowing treatment with clozapine // World Journal of Biological Psychiatry. - 2009. V. 10(1). - P. 70-3.201. Park J.Y., Shon J.H., Kim K.A., Jung H.J., Shim J.C., Yoon Y.R., Cha I.J., ShinJ.G.
Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on thepharmacokinetics and pharmacodynamics of haloperidol in healthy subjects // Journalof Clinical Psychopharmacology. - 2006. - V. 26. - P. 135-42.202. Pasa S., Sayhan M.B., Boyraz T., Urakci Z., Altintas A. A case of neurolepticmalignant syndrome accompanied to an atypical antipsychotic agent: risperidone //Neurotoxicology. - 2008. - V.
29(4). - P. 750-1.155203. Paton C., Barnes T.R., Cavanagh M.-R., Taylor D., Lelliott P. High-dose andcombination antipsychotic prescribing in acute adult wards in the UK: the challengesposed by p.r.n. prescribing // British Journal of Psychiatry. - 2008. - V. 192. - P. 435-9.204. Pelonero A.L., Levenson J.L., Pandurangi A.K. Neuroleptic MalignantSyndrome: A Review // Psychiatric Services. - 1998. - V.
49. - P. 1163-72.205. Pierdevara L., Ventura I.M., Eiras M., Gracias A.M. B., da Silva C.S. Anexperience with the Global Trigger Tool methodology for the study of adverse events ina medical ward // Journal of Nursing Referência. - 2016. - IV (9). – P. 97-105.206. Pierre J.M. Extrapyramidal symptoms with atypical antipsychotics: incidence,prevention and management // Drug Safety. - 2005. - V.
28. - P. 191-208.207. Plesnicar B.K., Zalar B., Breskvar K., Dolzan V. The influence of the CYP2D6polymorphism on psychopathological and extrapyramidal symptoms in the patients onlong-term antipsychotic treatment // Journal of Psychopharmacology. - 2006. - V.
20(6).- P. 829-33.208. Potkin S.G., Thyrum P.T., Alva G., Bera R., Yeh C., Arvanitis L.A. The safetyand pharmacokinetics of quetiapine when coadministered with haloperidol, risperidoneor thioridazine // Journal of Clinical Psychopharmacology. - 2002. - V.22. - P. 121-30.209. Prince M., Patel V., Saxena S., Maj M., Maselko J., Phillips M.R., Rahman A. Nohealth without mental health // The Lancet.
- 2007. - V. 370(9590). - P. 859-77.210. Psychosis and Schizophrenia in Adults: Treatment and Management. ClinicalGuideline CG178. National Institute for Health and Care Excellence (NICE); London,UK: 2014.211. Ramamoorthy A., Flockhart D.A., Hosono N., Kubo M., Nakamura Y., SkaarT.C. Differential quantification of CYP2D6 gene copy number by four differentquantitative real-time PCR assays // Pharmacogenetics and Genomics. - 2010. - V.20(7).
- P. 451-4.212. Rana A.Q., Chaudry Z.M., Blanchet P.J. New and emerging treatments forsymptomatic tardive dyskinesia // Journal of Drug Design, Development and Therapy. 2013. - V. 7. - P. 1329–40.156213. Ravyn D., Ravyn V., Lowney R., Nasrallah H.A. CYP450 pharmacogenetictreatment strategies for antipsychotics: a review of the evidence // SchizophreniaResearch. - 2013. - V.
149. - P. 1-14.214. Remington G., Kapur S. D2 and 5-HT2 receptor effects of antipsychotics:bridging basic and clinical findings using PET // The Journal of Clinical Psychiatry. 1999. - V. 60(Suppl 10). - V. 15-9.215. Restricted re-introduction of the atypical antipsychotic sertindole (Serdolect) MHRA,2002.URL:http://webarchive.nationalarchives.gov.uk/20110505062033/http://www.mhra.gov.uk/PrintPreview/DefaultSP/CON019523 (дата обращения 11.08.2017)216. Rettenbacher M.A., Hofer A., Eder U., Hummer M., Kemmler G., Weiss E.M.,Fleischhacker W.W. Compliance in schizophrenia: psychopathology, side effects, andpatients' attitudes toward the illness and medication // The Journal of ClinicalPsychiatry.
- 2004. - V. 65 (9). - P. 1211-8.217. Reynolds G.P., Zhang Z.J., Zhang X.B. Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism // Lancet. - 2002. - V.359. - P. 2086-7.218. Risgaard B., Waagstein K., Winkel B.G., Jabbari R., Lynge T.H., Glinge C., AlbertC., Correll C.U., Haunsø S., Fink-Jensen A., Tfelt-Hansen J. Sudden cardiac death inyoung adults with previous hospital-based psychiatric inpatient and outpatienttreatment: a nationwide cohort study from Denmark // The Journal of ClinicalPsychiatry.
- 2015. - V. 76(9). - P. 1122-9.219. Rochon P.A., Stukel T.A., Sykora K., Gill S., Garfinkel S., Anderson G.M.,Normand S.L., Mamdani M., Lee P.E., Li P., Bronskill S.E., Marras C., Gurwitz J.H.Atypical antipsychotics and parkinsonism // Archives of Internal Medicine.
- 2006. - V.165. - P. 1882-8.220. Rodriguez S., Gaunt T.R., Day I.N.M. Hardy-Weinberg Equilibrium Testing ofBiological Ascertainment for Mendelian Randomization Studies // American Journal ofEpidemiology. - 2009. - V. 169(4). - P. 505-14.157221. Roh H.K., Chung J.Y., Oh D.Y., Park C.S., Svensson J.O., Dahl M.L., BertilssonL. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but nothigh doses of haloperidol in Korean schizophrenic patients // The British Journal ofPsychiatry. - 2001. - V. 52.
- P. 265-71.222. Rosenheck R., Perlick D., Bingham S., Liu-Mares W., Collins J., Warren S.,Leslie D., Allan E., Campbell E.C., Caroff S., Corwin J., Davis L., Douyon R., Dunn L.,Evans D., Frecska E., Grabowski J., Graeber D., Herz L., Kwon K., Lawson W., MenaF., Sheikh J., Smelson D., Smith-Gamble V. Department of Veterans AffairsCooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness andcost of olanzapine and haloperidol in the treatment of schizophrenia: a randomizedcontrolled trial // Journal of the American Medical Association. - 2003. - V.
290. - P.2693-702.223. Rosenheck R.A. Open forum: effectiveness versus efficacy of second generationantipsychotics: haloperidol without anticholinergics as a comparator // PsychiatricServices. - 2005. - V. 56. - P. 85-92.224. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W.,Davis J.M., Leucht S. Second-Generation Antipsychotic Drugs and Extrapyramidal SideEffects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons //Schizophrenia Bulletin.
- 2012. V. 38(1). - P. 167-77.225. Ryu S.W., Kim Y.J., Kim E. Mutation analysis of CYP2D6 locus in the Koreanpopulation: identification of rare poor metabolizer alleles at the nucleotide level //Molecules and Cells. - 1998. - V. 8. - P. 758-63.226. Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in aCaucasian population: allele frequencies and phenotypic consequences // AmericanJournal of Human Genetics. - 1997. - V.
60. - P. 284-95.227. Sadock B.J., Sadock V.A., Sussman N. Kaplan & Sadock's Pocket Handbook ofPsychiatric Drug Treatment (4th Edition). Lippincott Williams & Wilkins, Inc., PA,USA, 2006.158228. Salahudeen M.S., Duffull S.B., Nishtala P.S. Anticholinergic burden quantifiedby anticholinergic risk scales and adverse outcomes in older people: a systematic review// BMC Geriatrics. - 2015.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
